Skip to main
VANI
VANI logo

VANI Stock Forecast & Price Target

VANI Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vivani Medical Inc. has demonstrated promising potential in the development of its NPM-139 compound, which may enhance the safety and tolerability profiles of existing treatments for chronic diseases, particularly semaglutide. The encouraging data showcasing a maintained weight loss of approximately 20% over six months indicates a strong therapeutic efficacy, which could drive higher patient compliance and lower therapy discontinuation rates. This supportive data lays a solid foundation for the advancement of NPM-139 into clinical development, thereby bolstering the company's growth prospects.

Bears say

Vivani Medical Inc faces significant risks that adversely impact its financial outlook, particularly regarding its lead product, NPM-139, which is currently undergoing clinical trials. The potential for failure in clinical trials and the subsequent inability to secure regulatory approval poses a substantial threat to the company's viability and market penetration. Additionally, the risk of dilution further exacerbates concerns for investors, as it may dilute shareholder value amid uncertainties in achieving commercial success in a competitive market.

VANI has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vivani Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vivani Medical Inc (VANI) Forecast

Analysts have given VANI a Strong Buy based on their latest research and market trends.

According to 1 analysts, VANI has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vivani Medical Inc (VANI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.